Chronic myeloid leukemia (CML) is a malignant clonal disease derived from hematopoietic stem cells, and it manifests itself through characteristic molecular markers: the bcr-abl fusion gene and the expression of p210 bcr-abl fusion protein. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.